It’s as simple as this...I believe that leronlimab binds
It’s as simple as this...I believe that leronlimab binds to ccr5 and leads to a multitude of life prolonging/saving/enhancing benefits in a host of diseases. Including covid (as it has literally proven that already).
If it takes a little (in the grand scheme of what this drug can eventually do, yes it’s little) more time to get there, fine with me.
I didn’t buy the stock, I bought the science. The science is worth a lot more than what the stock price says it is. No doubt about that. And I have no problem waiting until the price catches up to the long term reality that I so vividly still see.
Side note: new trial protocol will be tight and designed to slam dunk. Lessons learned, slight modification, EUA around the corner, then full approval. Possible interim surprise of selling elsewhere is still achievable on any given day.
Oh yea, EIND fully operational...I wonder why that is.... hmmmm
LONG
AND
STRONG
17
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...
Continue Reading
A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...
Continue Reading
First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...
Continue Reading
Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...
Continue Reading
Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...
Continue Reading
A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...
Continue Reading
A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...
Continue Reading
Top 5 Most Recently Viewed Articles
Alterity Therapeutics to Present at a Virtual Healthcare Conference Alterity Therapeutics, a biotechnology firm dedicated to developing treatments for neurodegenerative diseases, has recently announced its participation in an upcoming healthcare virtual conference. The event will shine a spotlight on influential healthcare companies and their innovative approaches to...
Continue Reading
Update for Investors in Toronto-Dominion Bank Kahn Swick & Foti, LLC, led by the experienced former Louisiana Attorney General Charles C. Foti, Jr., is reminding investors that significant changes are arriving for shareholders of Toronto-Dominion Bank (NYSE: TD). As the legal landscape evolves, those who experienced losses may want to take immediate action regarding their...
Continue Reading
GCC Reports Significant First Quarter Financials GCC, S.A.B. de C.V. (BMV: GCC*), recognized as a premier supplier and producer of cement, concrete, and aggregates, has shared its financial results for the first quarter. Despite facing various challenges, GCC's performance metrics reveal a resilience that is noteworthy. Q1 2025 Highlights In the first quarter of 2025, GCC...
Continue Reading
Overview of Recent Market Movements in Indonesia Indonesia's stock market experienced a downturn at the close of trading, influenced by various sectors showing significant losses. The IDX Composite Index reflected a decrease of 0.98%, marking a notable dip to a one-month low. This downturn is primarily attributed to declines in several key sectors, including...
Continue Reading
Blink Charging Receives Prestigious OCPP 2.0.1 Certification Blink stands out as one of just five EV charging companies in the U.S. to earn this coveted certification. Bowie, Md. – Blink Charging Co. (NASDAQ: BLNK), a prominent name in electric vehicle (EV) charging equipment and services, has proudly announced that its Series 7, 8, and 9 charger models have...
Continue Reading